69 related articles for article (PubMed ID: 18021497)
21. Facilitated bone mineral density testing versus hospital-based case management to improve osteoporosis treatment for hip fracture patients: additional results from a randomized trial.
Morrish DW; Beaupre LA; Bell NR; Cinats JG; Hanley DA; Harley CH; Juby AG; Lier DA; Maksymowych WP; Majumdar SR
Arthritis Rheum; 2009 Feb; 61(2):209-15. PubMed ID: 19177538
[TBL] [Abstract][Full Text] [Related]
22. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
[TBL] [Abstract][Full Text] [Related]
23. Teriparatide following bisphosphonates: initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest.
Jobke B; Pfeifer M; Minne HW
Connect Tissue Res; 2009; 50(1):46-54. PubMed ID: 19212852
[TBL] [Abstract][Full Text] [Related]
24. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence.
Balu S; Simko RJ; Quimbo RM; Cziraky MJ
Curr Med Res Opin; 2009 Nov; 25(11):2765-75. PubMed ID: 19785511
[TBL] [Abstract][Full Text] [Related]
25. Real-world clinical and economic outcomes for daily teriparatide patients in Japan.
Burge R; Sato M; Sugihara T
J Bone Miner Metab; 2016 Nov; 34(6):692-702. PubMed ID: 26661475
[TBL] [Abstract][Full Text] [Related]
26. Methodology for identifying patients at high risk for osteoporotic fracture.
Westfall G; Littlefield R; Heaton A; Martin S
Clin Ther; 2001 Sep; 23(9):1570-88. PubMed ID: 11589269
[TBL] [Abstract][Full Text] [Related]
27. Health plans turn their attention to the costs, complications of osteoporosis.
Dis Manag Advis; 2004 Nov; 10(11):125-7, 121. PubMed ID: 15682785
[TBL] [Abstract][Full Text] [Related]
28. Are EMS call volume predictions based on demand pattern analysis accurate?
Brown LH; Lerner EB; Larmon B; LeGassick T; Taigman M
Prehosp Emerg Care; 2007; 11(2):199-203. PubMed ID: 17454807
[TBL] [Abstract][Full Text] [Related]
29. [Breakthrough in the treatment of osteoporosis].
Brixen KT; Langdahl BL; Christensen PM; Ejersted CA
Ugeskr Laeger; 2004 Aug; 166(32):2649. PubMed ID: 15347164
[No Abstract] [Full Text] [Related]
30. [Bone anabolic drug for severe osteoporosis. Forsteo available on the German market].
Krankenpfl J; 2003; 41(10-12):240. PubMed ID: 14746212
[No Abstract] [Full Text] [Related]
31. Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis.
Cramer JA; Silverman SL; Gold DT
Curr Med Res Opin; 2007 Oct; 23(10):2369-77. PubMed ID: 17711617
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of step therapy policies for specialty pharmaceuticals in immune disorders.
Kozma CM; Ingham M; Paris A; Ellis L
J Med Econ; 2015; 18(8):646-53. PubMed ID: 25830699
[TBL] [Abstract][Full Text] [Related]
33. Statistical short-term earthquake prediction.
Kagan YY; Knopoff L
Science; 1987 Jun; 236(4808):1563-7. PubMed ID: 17835741
[TBL] [Abstract][Full Text] [Related]
34. Predicting outcome in coronary disease. Statistical models versus expert clinicians.
Lee KL; Pryor DB; Harrell FE; Califf RM; Behar VS; Floyd WL; Morris JJ; Waugh RA; Whalen RE; Rosati RA
Am J Med; 1986 Apr; 80(4):553-60. PubMed ID: 3963036
[TBL] [Abstract][Full Text] [Related]
35. The promise of molecular biology: efficacy, safety, wallet depletion.
Clough JD
Cleve Clin J Med; 2003 Jul; 70(7):584. PubMed ID: 12882380
[No Abstract] [Full Text] [Related]
36. [Drug utilization by older persons. II].
Kotoucková M; Springer V; Holubanská K; Blahútová A
Cesk Zdrav; 1987 Sep; 35(8-9):389-95. PubMed ID: 3664783
[No Abstract] [Full Text] [Related]
37. [Drug utilization in older persons. I].
Kotoucková M; Springer V; Majtás J; Zahradník A
Cesk Zdrav; 1987 May; 35(5):226-34. PubMed ID: 3594631
[No Abstract] [Full Text] [Related]
38. Accuracy of pharmaceutical company licensing predictions: projected versus actual licensing dates.
Doos L; Ward D; Stevens A; Packer C
J Pharm Health Serv Res; 2016 Jun; 7(2):117-122. PubMed ID: 27668015
[TBL] [Abstract][Full Text] [Related]
39. Concerning high and low utilizers of service in a medical care plan, and the persistence of utilization levels over a three year period.
DENSEN PM; SHAPIRO S; EINHORN M
Milbank Mem Fund Q; 1959 Jul; 37(3):217-50. PubMed ID: 13674069
[No Abstract] [Full Text] [Related]
40. [Mathematical model for the prediction of drug consumption. I. Correlative analysis of consumption factors].
Federmann J; Fikr V
Cesk Zdrav; 1970 Feb; 18(2):65-73. PubMed ID: 5417426
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
